Your session is about to expire
← Back to Search
Lacrimal Stent
Sinopsys Lacrimal Stent for Sinus Infection (SLS Trial)
Phase < 1
Waitlist Available
Research Sponsored by Sinopsys Surgical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 weeks
Awards & highlights
Summary
The purpose of this study is to collect preliminary clinical data related to the safety and performance of the Sinopsys Lacrimal Stent.
Eligible Conditions
- Sinus Infection
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 18 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Patency will be confirmed post procedure with passive flow through the SLS lumen by instilling 2-4 drops of sterile saline into the stented medial fornix and observing drainage.
SNOT - 20
Safety: Incidence and occurrence of anticipated and unanticipated adverse events
Secondary outcome measures
Lund-Kennedy Nasal Endoscopy Scores
Lund-MacKay CT Scores
Trial Design
1Treatment groups
Experimental Treatment
Group I: Sinopsys Lacrimal StentExperimental Treatment1 Intervention
The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sinopsys Lacrimal Stent
2015
Completed Early Phase 1
~20
Find a Location
Who is running the clinical trial?
Sinopsys SurgicalLead Sponsor
3 Previous Clinical Trials
22 Total Patients Enrolled
Teena AugustinoStudy DirectorSinopsys Surgical Inc.
Share this study with friends
Copy Link
Messenger